Medicares $50 obesity drug program sees huge demand
#Medicare #ObesityDrugsMedicare's $50 monthly obesity drug program, launched in July, has filled over 200,000 prescriptions at CVS and Walgreens. The Bridge program targets eligible beneficiaries, though those with sleep apnea or diabetes are excluded. Demand exceeded expectations, with millions potentially qualifying. read more
Telehealth firms block obesity drug access, patients frustrated
#Telehealth #ObesityDrugsTelehealth companies like Vida Health now gatekeep GLP-1 drugs for employers, requiring patients to meet extra lifestyle program rules before obtaining coverage, often causing frustration and treatment delays despite primary care prescriptions. read more
Insurance Cuts Off Weight-Loss Drugs, Patients Scramble
#ObesityDrugs #InsuranceCoverageInsurance coverage for GLP-1 obesity drugs like Wegovy and Zepbound is declining, forcing patients to pay high out-of-pocket costs or switch medications. Many face restrictive policies, leaving them to navigate financial and medical uncertainty alone. read more